Journal of Gastrointestinal Surgery

, Volume 22, Issue 6, pp 1052–1058 | Cite as

The Influence of Screening on Outcomes of Clinically Locally Advanced Rectal Cancer

  • A. M. Dinaux
  • L. G. J. Leijssen
  • L. G. Bordeianou
  • H. Kunitake
  • D. L. Berger
Original Article



Screening for colorectal cancer has resulted in declining incidence rates of both colon and rectal cancer and it may influence stage at presentation and improve survival. The aim of this study was to assess the impact of screening on patients diagnosed with locally advanced rectal cancer.


A retrospective analysis of a consecutive series of patients who underwent neoadjuvant therapy and had an R0-resection for clinical AJCC stage II or stage III disease. All patients received surgery at a single center between 2004 and 2015. Patients diagnosed through screening were compared to patients diagnosed through symptomatic presentation.


Three hundred nine patients were included, of whom 43 (13.9%) were diagnosed through screening. Screened patients had more often a white ethnicity, while there were no other differences in baseline characteristics or median household income. Screened patients had a lower rate of disease recurrence in addition to a longer disease free survival and overall survival.


Patients with locally advanced rectal cancer diagnosed through screening demonstrated more favorable short and long-term outcomes than patients diagnosed through symptoms. Findings of this study reinforce the need for screening programs in addition to the need for research regarding optimization of screening adherence.


Rectal cancer Screening Locally advanced disease Neoadjuvant therapy 


Compliance with Ethical Standards

Grant Support

AD received a grant from the Michael van Vloten foundation.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7–30. Scholar
  2. 2.
    Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–241. Scholar
  3. 3.
    Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624–1633. Scholar
  4. 4.
    Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the italian randomized controlled trial—SCORE. J Natl Cancer Inst. 2011;103(17):1310–1322. Scholar
  5. 5.
    Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy N Engl J Med. 2012;366(25):2345–2357. Scholar
  6. 6.
    Stock C, Pulte D, Haug U, Brenner H. Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointest Endosc. 2012;75(3):621–630.e1. Scholar
  7. 7.
    Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev 2012;21(3):411–416. Scholar
  8. 8.
    Lindebjerg J, Osler M, Bisgaard C. Colorectal cancers detected through screening are associated with lower stages and improved survival. Dan Med J. 2014;61(1):1–5.Google Scholar
  9. 9.
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology—rectal cancer (Version 3.2017). Accessed on May 5, 2017.
  10. 10.
    Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. Jama 2014;312(6):606–615. Scholar
  11. 11.
    Chand M, Siddiqui MRS, Swift I, Brown G. Systematic review of prognostic importance of extramural venous invasion in rectal cancer. World J Gastroenterol 2016;22(4):1721–1726. Scholar
  12. 12.
    Hogan J, Chang KH, Duff G, et al. Lymphovascular invasion: a comprehensive appraisal in colon and rectal adenocarcinoma. Dis Colon rectum 2015;58(6):547–555. Scholar
  13. 13.
    Chand M, Swift RI, Tekkis PP, Chau I, Brown G. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 2014;110(1):19–25. Scholar
  14. 14.
    Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22(10):1785–1796. Scholar
  15. 15.
    Dinaux AM, Amri R, Bordeianou LG, et al. The impact of pathologic complete response in patients with neoadjuvantly treated locally advanced rectal cancer—a large single-center experience. J Gastrointest Surg 2017.
  16. 16.
    Kim JH, Beets GL, Kim MJ, Kessels AGH, Beets-Tan RGH. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 2004;52(1):78–83. Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • A. M. Dinaux
    • 1
  • L. G. J. Leijssen
    • 1
  • L. G. Bordeianou
    • 1
  • H. Kunitake
    • 1
  • D. L. Berger
    • 1
    • 2
  1. 1.Department of General and Gastrointestinal SurgeryMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Massachusetts General Hospital Division of General Surgery & Gastrointestinal SurgeryBostonUSA

Personalised recommendations